145 related articles for article (PubMed ID: 14571765)
21. Serum iron parameters in patients with alcoholic and chronic cirrhosis and hepatitis.
Jurczyk K; Wawrzynowicz-Syczewska M; Boroń-Kaczmarska A; Sych Z
Med Sci Monit; 2001; 7(5):962-5. PubMed ID: 11535942
[TBL] [Abstract][Full Text] [Related]
22. Iron overload in patients with chronic viral hepatitis: how common is it?
Riggio O; Montagnese F; Fiore P; Folino S; Giambartolomei S; Gandin C; Merli M; Quinti I; Violante N; Caroli S; Senofonte O; Capocaccia L
Am J Gastroenterol; 1997 Aug; 92(8):1298-1301. PubMed ID: 9260793
[TBL] [Abstract][Full Text] [Related]
23. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C.
Fujita N; Sugimoto R; Ma N; Tanaka H; Iwasa M; Kobayashi Y; Kawanishi S; Watanabe S; Kaito M; Takei Y
J Viral Hepat; 2008 Jul; 15(7):498-507. PubMed ID: 18331251
[TBL] [Abstract][Full Text] [Related]
24. Hepatic iron, serum indices of iron status and chronic hepatitis C: activity, stage and response to therapy.
Van Thiel DH; Colantoni A; De Maria N
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):402-4. PubMed ID: 9789137
[No Abstract] [Full Text] [Related]
25. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
26. The advantage of gastrectomized patients in management of their chronic hepatitis C.
Hayashi H; Takikawa T; Arai N; Yano M
Nagoya J Med Sci; 1997 Nov; 60(3-4):119-27. PubMed ID: 9481091
[TBL] [Abstract][Full Text] [Related]
27. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
30. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
[TBL] [Abstract][Full Text] [Related]
31. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
32. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
[TBL] [Abstract][Full Text] [Related]
33. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
[TBL] [Abstract][Full Text] [Related]
34. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
Kurosaki M; Matsunaga K; Hirayama I; Tanaka T; Sato M; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Asahina Y; Miyake S; Enomoto N; Izumi N
J Hepatol; 2008 May; 48(5):736-42. PubMed ID: 18329125
[TBL] [Abstract][Full Text] [Related]
35. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
36. Therapy of hepatitis C: other options.
Bonkovsky HL
Hepatology; 1997 Sep; 26(3 Suppl 1):143S-151S. PubMed ID: 9305680
[TBL] [Abstract][Full Text] [Related]
37. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C.
Sebastiani G; Vario A; Ferrari A; Pistis R; Noventa F; Alberti A
J Viral Hepat; 2006 Mar; 13(3):199-205. PubMed ID: 16475996
[TBL] [Abstract][Full Text] [Related]
38. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.
Aoki CA; Rossaro L; Ramsamooj R; Brandhagen D; Burritt MF; Bowlus CL
J Clin Gastroenterol; 2005 Jan; 39(1):71-4. PubMed ID: 15599216
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin in the treatment of hepatitis C.
Abonyi ME; Lakatos PL
Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
[TBL] [Abstract][Full Text] [Related]
40. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
